Cancer Care Adds Ovarian Cancer Section to Website

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

NEW YORK--Cancer Care, Inc. has launched a new online resource for ovarian cancer patients and their families and friends. A new section added to Cancer Care’s website (www.cancercare.org) offers a comprehensive overview of ovarian cancer and a resource guide.

NEW YORK--Cancer Care, Inc. has launched a new online resource for ovarian cancer patients and their families and friends. A new section added to Cancer Care’s website (www.cancercare.org) offers a comprehensive overview of ovarian cancer and a resource guide.

The new addition to the website is made possible through an educational grant from SmithKline Beecham Oncology. The ovarian cancer section complements Cancer Care’s other website sections on specific types of cancer such as breast, prostate, lung, colon, brain, and melanoma.

Information provided about the disease includes tumor differentiation and staging, risk factors, coping, and diagnostic and treatment options. Answers to common questions about ovarian cancer are also included.

"We wanted ovarian cancer patients to be able to address any technical or practical concerns they have regarding the disease," said Diane Blum, MSW, executive director of Cancer Care. "This website section, as with all of Cancer Care’s website sections, encourages patients to utilize all available resources for their medical, emotional, and financial needs. We believe it will help connect patients with essential resources."

Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content